Společnost Dentsply Sirona od 1. listopadu 2026 rozšíří distribuci digitálních stomatologických technologií v USA prostřednictvím společnosti Midwest Dental Equipment & Supply.
Key Takeaways Dentsply Sirona expands its Midwest Dental agreement to offer its technology portfolio from Nov. 1, 2026.The deal widens access to digital dentistry solutions through Midwest Dental's sales and technical network.XRAY's seventh North American dealer enhancement in 2026 aims to grow commercial reach and digital adoption. Dentsply Sirona (XRAY - Free Report) recently announced expansion of its U.S. commercial reach through an enhanced distribution agreement with Midwest Dental Equipment & Supply. Effective Nov. 1, 2026, the distributor will be offering Dentsply Sirona’s technology portfolio in the United States, extending a relationship that has primarily focused on consumables. The agreement marks the company’s seventh North American dealer partnership enhancement announced this year.
Per management, the expanded partnership will extend access to Dentsply Sirona’s connected technology ecosystem through Midwest Dental’s established customer relationships and local expertise. The collaboration is designed to help dental practices improve efficiency, simplify workflows and support long-term growth.
XRAY Stock Trend Following the NewsXRAY stock has gained 3.6% since the announcement on Tuesday. Year to date, the stock fell 22.8% against the industry’s 6% growth and the S&P 500’s 14.6% rise.
The expanded distribution network could create additional sales opportunities for Dentsply Sirona by putting its digital dentistry products in front of a broader customer base. Access to Midwest Dental’s established customer relationships and local technical support may help reduce barriers to purchasing and adopting advanced dental equipment. If these efforts translate into stronger demand for XRAY’s digital dentistry products, they could support growth in the company’s technology business, although the deal’s financial contribution has not been disclosed.
XRAY currently has a market capitalization of $1.76 billion.
Image Source: Zacks Investment Research
More on the NewsThe expanded agreement will provide dental professionals with greater access to Dentsply Sirona’s digital dentistry solutions through Midwest Dental’s established network of sales representatives, service technicians and technical specialists. Midwest Dental is the largest independent, family-owned dental distributor in the Southern United States, serving dental professionals nationwide. Its sales, service and technical teams operate across Texas, Oklahoma, New Mexico and Arkansas.
Dentsply Sirona’s other distribution developments include new technology distribution agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company and Medline Sinclair, alongside a renewed partnership with Patterson Dental.
Through these distribution initiatives, Dentsply Sirona is working to strengthen its commercial reach, improve access to its connected technology portfolio and accelerate adoption of its digital dentistry solutions across major North American markets.
Industry Prospects Favoring the MarketAccording to Fortune Business Insights, the global digital dentistry market is projected to grow from $5.47 billion in 2026 and is projected to witness a CAGR of 9.3% through 2034.
Factors like the rising demand for cosmetic dentistry, technological advancements and the increasing prevalence of dental disorders are supporting market growth.
Other NewsRecently, Dentsply Sirona’s subsidiary Wellspect HealthCare announced that its Surity Urinary Management System and male and female external catheters may qualify for traditional U.S. Medicare coverage for eligible patients when medically necessary. The reimbursement access aims to reduce barriers to non-invasive urinary incontinence management, expanding patient choice and supporting comfortable, discreet at-home care.
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Dentsply Sirona získala souhlas věřitelů se zmírněním dluhových podmínek pro čtvrtletí končící v září a prosinci 2026, včetně vyšších limitů zadlužení.
What happened Dentsply Sirona Inc. (NASDAQ: XRAY) said on October 8, 2026, that lenders consented to amendments to its revolving credit facility and related note agreements. The company entered the Third Amendment to Credit Agreement, dated September 30, 2026, and three Note Purchase Agreement Amendments for the 2015, 2016 and 2019 notes.
The amendments raise the maximum permitted Total Leverage Ratio and Senior Leverage Ratio for the fiscal quarters ending September 30, 2026 and December 31, 2026. They also allow an additional EBITDA addback for certain cash charges or expenses in those quarters. The Third Amendment adds a new pricing level for the applicable margin and facility fee, and the note amendments raise incremental interest if total leverage reaches specified thresholds.
The initial Aggregate Commitment is $700 million, and each Swingline Loan must be at least $1 million. Key numbers Metric Latest Change Source Initial Aggregate Commitment $700 million Third Amendment to Credit Agreement Swingline Loan minimum $1 million Third Amendment to Credit Agreement Swingline minimum as share of commitment 0.14% Calculated from Third Amendment to Credit Agreement Read more: Dentsply Sirona (XRAY) stock analysis and investment case
Why it matters OptimistFi's case is that Dentsply Sirona is a self-help dental-franchise repair story, where scale and product breadth must stop revenue leakage and rebuild cash earnings. This filing is mixed because it gives the company more covenant room, but it does so through lender-approved amendments rather than operating improvement. The filing says the revised terms are intended to allow the company to stay in compliance with its debt covenants in all material respects.
It also gives lenders more visibility through the new quarterly reporting package. That matters because the company is paying for flexibility with tighter limits, new reporting and pricing terms while leverage stays in focus. The $1 million Swingline minimum is about 0.14% of the $700 million initial commitment. The amendment is a financing bridge, not a turnaround by itself. It keeps the capital structure manageable while management works on operations.
Browse: stock research on every company OptimistFi covers
What's next The next dated checkpoint is the compliance certificate for the fiscal year ending December 31, 2026. The quarterly disclosures on initiatives, costs and savings are the next scheduled updates under the package.
Until that certificate is delivered, the package generally bars new liens and new subsidiary debt, with carveouts, and limits restricted payments. If those reports and the year-end certificate show leverage staying inside the amended limits, the amendment supports the case. If not, the added restrictions stay in force. The quarterly schedule is the next live test of the deal.
More from OptimistFi XRAY stock: the Dentsply Sirona thesis, its status and the next test to watch Levi Strauss & Co. (NYSE: LEVI) Raises Profit as Wholesale Outruns DTC Park Aerospace Corp. (NYSE: PKE) Expands Profit as Sales Rise Helen of Troy Limited (NASDAQ: HELE) Lifts Profit as Cash Flow Rebounds Stock research on every company OptimistFi covers Latest stock research and investment-case updates OptimistFi: evidence-first equity research Sources SEC 8-K — Current report filed October 8, 2026. Third Amendment to Credit Agreement — Exhibit 4.1 with the initial Aggregate Commitment and Swingline terms. Read the full OptimistFi thesis on Dentsply Sirona Inc.: https://optimistfi.com/stocks/XRAY
See what would break the Dentsply Sirona Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Dentsply Sirona Inc. investment case, its status and the next test to watch live on the Dentsply Sirona Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
Portfolio Surity společnosti Wellspect HealthCare může být u oprávněných příjemců v USA hrazeno z tradičního programu Medicare, pokud je to zdravotně nezbytné.
Traditional Medicare reimbursement supports broader access to non-invasive management options for eligible beneficiaries living with permanent urinary incontinence MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.
The Surity™ portfolio provides non-invasive management solutions for individuals living with urinary incontinence and is designed to make everyday urine management more comfortable, discreet and reliable. Coding verification under Healthcare Common Procedure Coding System (HCPCS) codes A6590 for the Surity™ Female and Male External Catheters and E2001 for the Surity™ Urinary Management System supports reimbursement access for beneficiaries who meet applicable coverage criteria.
“Medicare reimbursement for the Surity™ portfolio represents a significant milestone in our efforts to help individuals living with permanent urinary incontinence benefit from modern solutions that can support their day-to-day needs,” said Chris Schlenk, Group Vice President at Wellspect HealthCare. “For eligible beneficiaries with permanent urinary incontinence, newly established Medicare coding may help reduce barriers to care and expand choice in urinary management. This achievement reflects our ongoing commitment to helping individuals and their caregivers in managing important care needs with solutions designed to support comfort, confidence, and independence.”
For the more than 13 million people living with urinary incontinence in the U.S.,i access to management solutions that address care needs like comfort and rest can have meaningful impact. Traditional Medicare reimbursement access for the Surity™ portfolio helps provide eligible beneficiaries with a new choice, combining gentle suction technology with an intuitive design and features that support quiet operation and odor management, assisting in overnight care and bringing added reassurance to daily routines.
Following the introduction of the Surity™ Female and Male External Catheters earlier in 2026, Wellspect launched the Surity™ Urinary Management System in the United States on August 18, completing the full Surity portfolio. Since its introduction, Surity has become one of the most searched external catheter brands on Google.ii
For additional information* about Surity™, including traditional Medicare coverage requirements and eligibility, visit www.surity.care, where you can also connect with a Wellspect Reimbursement Specialist.
*Whether a product or service is covered by traditional Medicare depends on individual situations and Medicare’s requirements. Coverage, coding, and payment decisions are made by individual payers and may vary. Wellspect HealthCare does not guarantee coverage or reimbursement and is not responsible for payer determinations.
Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand [email protected]
About Wellspect HealthCare
Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY) is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.
With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.
Wellspect delivers solutions that support safe bladder and bowel management, while continuously enhancing the experience, clinical performance, and service quality for both healthcare professionals and the people in their care.
As one of the world’s leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.
Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.
With advanced Surity™, Wellspect provides reliable urinary incontinence care designed to restore comfort, rest, and confidence for people living with severe urinary incontinence and for their caregivers.
Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.
Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world’s largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.
_____________________________
i Leslie SW, Tran LN, Puckett Y. Urinary Incontinence. [Updated 2024 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559095/
ii Google Trends. External Catheter Brands. USA; 2026.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/962344d1-fb85-481b-a8e9-201183fbd79a
U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio The Surity™ portfolio may be covered by traditional Medicare for eligible beneficiaries when medical...
The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona’s North American dealer network and giving more customers access to its products and technology. | Source: DENTSPLY SIRONA Inc.
CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced an expanded relationship with Midwest Dental Equipment & Supply, an independent, family-owned distributor of dental supplies, equipment, and technology.
Effective November 1, 2026, Midwest Dental will begin offering Dentsply Sirona’s technology portfolio in the United States, building on a relationship that has historically focused on consumables. The expanded relationship increases access to Dentsply Sirona’s digital dentistry solutions through Midwest Dental’s network of sales, service, and technical specialists.
The agreement reflects continued execution against Dentsply Sirona’s commitment to broaden access to its connected technology portfolio by expanding relationships with trusted distribution partners across North America.
Together, these agreements support Dentsply Sirona’s commercial strategy to increase customer access, strengthen coverage in key markets and support adoption of the Company’s connected technology solutions.
Founded in 1988 and headquartered in Wichita Falls, Texas, Midwest Dental Equipment & Supply is the largest independent, family-owned distributor in the Southern U.S. serving dental professionals nationwide, with sales, service, and technical teams on the ground in Texas, Oklahoma, New Mexico, and Arkansas.
“Midwest Dental has built strong relationships across the markets it serves, from independent practices to larger customer groups, making it an important partner as we continue expanding access to connected dentistry,” said Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona. “By bringing our technology portfolio to Midwest Dental’s customers, we are extending the reach of a connected ecosystem designed to help practices improve efficiency, simplify workflows and support long-term growth.”
“Our customers trust us to help them make the best technology decisions that are right for their practice,” said Matt LeVasseur, Chief Executive Officer at Midwest Dental Equipment & Supply. “Adding Dentsply Sirona’s technology portfolio allows us to offer the industry’s leading and most complete digital dentistry solutions. When you add support from local service technicians, in-depth training and technical expertise, we’re able to exceed our customers’ expectations. In today’s busy marketplace, it is important for our customers to have an easy, seamless and profitable solution for same-visit crown restorations and Dentsply Sirona’s technology allows Midwest Dental to do that at the highest level”
The Midwest Dental agreement marks Dentsply Sirona’s seventh North American dealer partnership enhancement of 2026, following new technology agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company, and Medline Sinclair, as well as a renewed partnership with Patterson Dental. Together, these agreements support Dentsply Sirona’s commercial strategy to expand customer access, strengthen coverage in key markets and accelerate adoption of the Company’s connected technology solutions.
About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report) hit a new 52-week low on Friday . The company traded as low as $9.36 and last traded at $9.38, with a volume of 9306449 shares. The stock had previously closed at $10.14.
Analyst Upgrades and Downgrades Several brokerages recently commented on XRAY. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a research report on Monday, August 10th. BMO Capital Markets dropped their target price on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a “market perform” rating on the stock in a research report on Thursday. Barclays upped their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a research note on Monday, August 24th. Piper Sandler lifted their price objective on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $13.31.
Get Our Latest Stock Report on XRAY
DENTSPLY SIRONA Stock Performance The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $1.87 billion, a PE ratio of -3.41, a PEG ratio of 1.29 and a beta of 0.84. The firm has a 50 day moving average price of $11.96 and a 200-day moving average price of $11.51. DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. During the same quarter in the prior year, the firm earned $0.52 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts expect that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current fiscal year.
Institutional Inflows and Outflows Institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in DENTSPLY SIRONA during the second quarter worth about $283,405,000. Southpoint Capital Advisors LP acquired a new stake in shares of DENTSPLY SIRONA during the 1st quarter valued at about $116,000,000. Armistice Capital LLC grew its holdings in DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock valued at $83,416,000 after purchasing an additional 1,562,000 shares during the period. Invenomic Capital Management LP increased its holdings in DENTSPLY SIRONA by 17.9% in the 4th quarter. Invenomic Capital Management LP now owns 5,132,036 shares of the medical instruments supplier’s stock worth $58,659,000 after acquiring an additional 780,837 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DENTSPLY SIRONA during the second quarter worth about $47,780,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.
(Get Free Report)
DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental laboratories, and other oral health professionals with solutions spanning preventive, restorative, endodontic, orthodontic, implant, and prosthetic dentistry.
Its portfolio includes dental consumables, equipment and treatment centers, imaging systems, CAD/CAM systems, instruments, dental materials, implants, orthodontic products, and software and digital workflow solutions.
See Also Five stocks we like better than DENTSPLY SIRONA Aeluma’s Selloff Could Be Setting Up Its Next Big Move Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip? The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks The Fed’s Rate Hike Could Backfire If Oil Prices Collapse Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
Dentsply Sirona investuje do digitální stomatologie a restrukturalizace, ale slabší poptávka po vybavení, implantátech a SureSmile dál brzdí růst i marže. Ve 2. čtvrtletí tržby Orthodontic and Implant Solutions klesly na 197 milionů USD z 226 milionů USD.
Key Takeaways Dentsply Sirona is investing in digital dentistry, R&D and restructuring to support growth and profitability.XRAY's SureSmile revenues fell double digits; weaker implants and Byte's absence pressured segment sales.Tariffs, freight costs and weak equipment demand could delay XRAY's revenue recovery and margin improvement. DENTSPLY SIRONA (XRAY - Free Report) is well positioned for growth, driven by its investments in digital dentistry, R&D and commercial execution. However, weakness in CAD/CAM, implants and SureSmile, along with tariff and freight pressures, could weigh on near-term growth and profitability.
Shares of this Zacks Rank #3 (Hold) company have lost 11.3% year to date against the industry's 3.7% growth. The S&P 500 Index has also gained 10% in the same time frame.
XRAY, with a market capitalization of $1.96 billion, is a global leader in the design, development, manufacturing and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products. It anticipates earnings to improve 5.6% over the next five years.
Image Source: Zacks Investment Research
Factors Favoring XRAY’s GrowthDigital Dentistry Ecosystem Strength: Dentsply Sirona continues to build its digital dentistry presence through Primescan scanners, Primeprint 3D printing and the DS Core cloud platform. Rather than positioning these as standalone products, the company is integrating them into connected workflows designed to reduce chair time and improve clinical consistency. Smart View-Detect, an FDA-cleared AI diagnostic aid for CBCT scans, further expands this ecosystem. DS Core’s interoperability with third-party systems can also support greater utilization across the installed base. New distributor agreements, including the Benco Dental arrangement, could further broaden market access and support higher-value digital revenue over time.
Clear Aligner Market Opportunity: The shift toward clear aligners and digital treatment planning provides a longer-term opportunity for SureSmile. Second-quarter 2026 Orthodontic and Implant Solutions sales declined to $197 million from $226 million a year earlier, partly due to the absence of Byte and weaker implant volumes, while SureSmile revenues fell double digits to $40 million. Management continues investing in Ortho on DS Core, sales training and dealer expansion. Improved execution could help SureSmile generate greater pull-through for scanners, imaging, software and related consumables.
Restructuring and Innovation Investments: Dentsply Sirona’s 2026 restructuring plan targets approximately $120 million in annualized cost savings, allowing the company to fund growth initiatives while improving cost discipline. In the second quarter of 2026, R&D spending rose 20.3% year over year to $45 million. Six dealer and distribution expansions year-to-date and new product launches, including those supporting Wellspect’s growth, could improve commercial reach and portfolio performance. If execution remains consistent, these initiatives may support a more stable growth and profitability profile.
Downsides for XRAY StockSoft Equipment and Capital Spending: Equipment-related demand remains pressured by higher financing costs and cautious spending among dental practices, particularly in the United States. In the second quarter of 2026, Connected Technology Solutions sales declined 3.8% in constant currency, while Americas sales fell 11.6%. Although APAC CTS delivered double-digit growth and Equipment and Instruments was broadly flat, weakness in larger-ticket categories remains a concern. EMEA distributor destocking also weighed on sell-in. New dealer partnerships are showing early traction, but management expects a more meaningful revenue contribution from these initiatives beginning in the fourth quarter of 2026. Continued softness in equipment demand could delay revenue recovery and operating leverage.
SureSmile and Byte-Related Pressure: The discontinued Byte business continues to weigh on year-over-year comparisons. Orthodontic and Implant Solutions sales declined 14.9% in constant currency in the second quarter, including an $18 million impact from the absence of Byte. SureSmile revenues declined double digits, primarily in the Americas, while lower implant volumes added further pressure. Management is expanding dealer access and investing in clinical education, but a sustained recovery will depend on stronger commercial execution. Prolonged weakness in SureSmile or implants could keep the segment under pressure.
Tariffs Weigh on Margins: Tariffs and broader macroeconomic uncertainty remain risks to margins. In the first quarter, adjusted EBITDA margin declined 430 basis points, while gross margin fell 560 basis points due to lower volumes, unfavorable mix and tariff impacts. Although Dentsply Sirona received $44 million in tariff refunds during the second quarter, gross profit was still pressured by lower volumes, unfavorable sales mix and incremental tariff impacts. Management also noted higher freight costs related to geopolitical tensions. Restructuring and cost controls are helping offset some pressure, but persistent or broader tariffs could delay margin recovery and potentially require additional pricing or sourcing adjustments.
XRAY’s Estimate TrendThe Zacks Consensus Estimate for 2026 revenues is pegged at $3.57 billion, indicating a 3.1% decrease from the 2025 level.
The consensus mark for adjusted earnings per share is pinned at $1.56 for 2026, indicating a 2.5% year-over-year decline.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Inspire Medical Systems (INSP - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Inspire Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of 14 cents, which beat the Zacks Consensus Estimate by 163.6%. Revenues of $200.6 million surpassed the Zacks Consensus Estimate by 2.9%.
INSP has an estimated long-term earnings growth rate of 10.6%. INSP’s earnings surpassed estimates in the trailing four quarters, the average surprise being 195.9%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
DENTSPLY SIRONA (XRAY) ve 2. čtvrtletí 2026 překonala odhady zisku i tržeb a potvrdila celoroční výhled pro rok 2026. Tržby ale meziročně klesly o 4,1 % a provozní marže se snížila.
Key Takeaways XRAY topped Q2 earnings and revenue estimates while maintaining its full-year 2026 outlook.Wellspect Healthcare grew 7.1%, offsetting declines across XRAY's three dental segments.XRAY improved gross and EBITDA margins, but operating margin fell amid tariffs and lower volumes. DENTSPLY SIRONA Inc. (XRAY - Free Report) topped second-quarter 2026 earnings and revenue expectations while keeping its full-year outlook intact. The results showed better cash generation and selected margin gains, but they did not mark a broad recovery in dental demand.
The post-earnings question is whether those improvements can outweigh falling sales, tariff pressure and continued weakness in equipment, orthodontics and implants. Wellspect Healthcare remained the clearest growth offset.
XRAY’s Q2 Beat Came With Lower RevenueAdjusted earnings of 52 cents per share beat the Zacks Consensus Estimate of 36 cents by 44.4%. Revenues of $898 million topped the consensus estimate by 1.6%.
That beat came despite revenues falling 4.1% year over year as reported and 6.3% at constant currency. Weakness across three dental segments and the absence of Byte kept the quarter from signaling a broad sales recovery.
XRAY’s Wellspect Unit Provided the Bright SpotWellspect Healthcare revenues rose 7.1% to $86 million, supported by new product launches. Connected Technology Solutions fell 1.5%, Essential Dental Solutions declined 2.7% and Orthodontic and Implant Solutions dropped 13.2%.
The wider dental market is mixed. Align Technology, Inc. (ALGN - Free Report) reported 8.2% growth in second-quarter clear-aligner revenues, but its Imaging Systems and computer-aided design and manufacturing services revenues fell 10.8%. Envista Holdings Corporation (NVST - Free Report) reported 5.0% core sales growth, showing that industry demand is uneven rather than uniformly weak.
XRAY’s Margins Show a Mixed but Better PictureAdjusted gross margin improved 50 basis points to 56.4%, while adjusted EBITDA margin increased 20 basis points to 21.3%. Tariff refunds helped both measures.
Adjusted operating margin, however, contracted 240 basis points to 15.8%. Lower volumes, unfavorable mix, tariff costs and higher selling, general and administrative expenses and increased research and development spending continued to limit operating leverage.
XRAY’s Cash Flow Improves as Liquidity TightensSecond-quarter free cash flow increased to $55 million from $16 million a year earlier. First-half operating cash flow rose to $139 million from $55 million, aided by tariff refunds and better management of inventory and accounts payable.
Cash and cash equivalents stood at $239 million at June 30, down from $326 million at Dec. 31, 2025. The net debt-to-EBITDA ratio was 3.2, keeping balance-sheet flexibility and debt reduction important to the turnaround.
XRAY Keeps 2026 Guidance Despite Uneven DemandDentsply Sirona maintained its 2026 net sales outlook of $3.5 billion to $3.6 billion and adjusted earnings guidance of $1.40-$1.50 per share. Benefits from tariff refunds are excluded from the adjusted earnings outlook.
Maintaining guidance gives investors a clear second-half benchmark. A more durable recovery still depends on better equipment demand, stabilization in SureSmile and implants and improved conversion from the company’s expanded dealer network and commercial investments.
XRAY’s Scores Keep the Post-Earnings View BalancedThe quarter supports a measured view rather than a clean turnaround call. Better cash flow and some margin improvement are constructive, but sales contraction, tariffs and execution risk remain meaningful.
XRAY currently carries a Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of B, Momentum Score of F and VGM Score of B. The Value Score of A, Growth Score of B and VGM Score of B point to relatively favorable value, growth and blended characteristics, while the Momentum Score of F signals weak near-term momentum. Combined with a Hold rank, the setup remains balanced. While Envista Holdings sports a Zacks Rank #1 (Strong Buy), Align Technology carries a Zacks Rank of 3.You can see the complete list of today’s Zacks #1 Rank stocks here.
DENTSPLY SIRONA oznámila ve 2. čtvrtletí EPS 0,52 USD, nad odhadem 0,35 USD, a tržby 898 mil. USD, také nad konsensem. Tržby ale meziročně klesly o 4,1 %.
Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Free Report) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier’s stock after acquiring an additional 106,024 shares during the quarter. Empowered Funds LLC owned approximately 0.06% of DENTSPLY SIRONA worth $1,469,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. First Eagle Investment Management LLC grew its position in shares of DENTSPLY SIRONA by 3.2% in the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after buying an additional 458,744 shares during the last quarter. AQR Capital Management LLC boosted its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after acquiring an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in DENTSPLY SIRONA by 0.9% in the third quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after acquiring an additional 92,868 shares in the last quarter. Southpoint Capital Advisors LP purchased a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Finally, Armistice Capital LLC raised its holdings in shares of DENTSPLY SIRONA by 27.2% in the fourth quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier’s stock worth $83,416,000 after buying an additional 1,562,000 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.
Insider Activity at DENTSPLY SIRONA In other news, Director Brian P. Mckeon purchased 10,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Brian T. Gladden acquired 9,985 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 35,160 shares of company stock valued at $351,179. 0.46% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth Several analysts have weighed in on the company. Citigroup initiated coverage on DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. Mizuho dropped their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays cut their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Finally, UBS Group decreased their target price on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.54.
Read Our Latest Stock Report on XRAY
DENTSPLY SIRONA Stock Down 8.0% Shares of NASDAQ XRAY opened at $12.12 on Friday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -4.41, a price-to-earnings-growth ratio of 1.57 and a beta of 0.85. The company’s 50-day simple moving average is $11.77 and its 200-day simple moving average is $11.89. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52-week low of $9.40 and a 52-week high of $14.86.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current fiscal year.
DENTSPLY SIRONA News Summary Here are the key news stories impacting DENTSPLY SIRONA this week:
Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat. DENTSPLY SIRONA Company Profile (Free Report)
Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Recommended Stories Five stocks we like better than DENTSPLY SIRONA Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEDai ichi Life Insurance Company Ltd Acquires 12,401 Shares of Amazon.com, Inc. $AMZN
NEXT HEADLINE »Empowered Funds LLC Raises Holdings in Snap Inc. $SNAP
Dentsply International (XRAY - Free Report) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +44.44%. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.28 per share when it actually produced earnings of $0.27, delivering a surprise of -3.57%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Dentsply, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $898 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.60%. This compares to year-ago revenues of $936 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Dentsply shares have added about 20.6% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Dentsply?While Dentsply has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Dentsply was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.37 on $866.96 million in revenues for the coming quarter and $1.42 on $3.58 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 15% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Pro-Dex, Inc. (PDEX - Free Report) , has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of +86.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Pro-Dex, Inc.'s revenues are expected to be $19.2 million, up 9.8% from the year-ago quarter.
DENTSPLY SIRONA má 6. srpna po uzavření trhu oznámit výsledky za 2Q, přičemž výnosy se čekají kolem 883,9 milionu USD a upravený EPS 36 centů. Na ziskovost mohou dál tlačit restrukturalizace, snižování zásob dealerů a cla.
Key Takeaways XRAY is expected to post Q2 revenues near $884 million and adjusted EPS of 36 cents.Transformation spending, dealer inventory cuts and tariffs may pressure near-term profitability.Wellspect growth and resilient APAC demand may offset weakness in equipment, implants and Europe. DENTSPLY SIRONA Inc. (XRAY - Free Report) is scheduled to release second-quarter 2026 results on Aug. 6, after market close.
In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 3.57%. It delivered an average earnings surprise of negative 5.23% for the trailing four quarters.
XRAY’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $883.9 million. The consensus mark for earnings is pinned at 36 cents per share.
Our model estimates for revenues and adjusted earnings per share (EPS) are $884.8 million and 36 cents, respectively.
Factors to Note Ahead of XRAY’s Q2 ResultsDENTSPLY SIRONA's second-quarter 2026 performance is likely to have reflected continued execution of its Return-to-Growth action plan. The company remains focused on commercial restructuring, clinical education, innovation and cost optimization during the second quarter. While these initiatives are expected to strengthen long-term growth, they are likely to have weighed on near-term profitability due to higher investments. Per the first-quarter earnings call, management also indicated that meaningful benefits from the transformation plan are expected to build gradually, with a larger impact in the second half of 2026.
The second quarter is also likely to have been affected by dealer inventory adjustments linked to the transition toward a drop-ship model. Management expects this inventory burn to occur primarily from the second quarter through the remainder of the year. This dynamic is likely to have created a revenue headwind, particularly across equipment and connected technology products. Tariff-related costs, softer implant demand and continued weakness in certain European markets are also expected to have remained pressure points during the quarter.
From a segmental standpoint, Connected Technology Solutions is likely to have remained under pressure due to softer equipment demand and dealer inventory normalization. Orthodontic and implant sales may also have stayed weak as the company continues to rebuild commercial execution in these businesses. However, Wellspect Healthcare is expected to have maintained healthy growth, supported by new product adoption. Essential Dental Solutions could also have benefited if dealer destocking trends in Europe began to moderate, as management expects.
Geographically, the U.S. business is likely to have remained the company's primary focus. Management has been expanding distributor partnerships, strengthening its sales organization and increasing customer engagement to restore growth. International markets, particularly APAC, are expected to have remained relatively resilient, while Europe is likely to have faced some pressure from inventory destocking and macro uncertainty in the to-be-reported quarter.
Investors are likely to closely watch management's commentary on the pace of U.S. recovery, dealer inventory normalization and traction from new distribution agreements. Updates on the implants turnaround, commercial execution and early adoption of recently launched products will also be in focus. Any indication that restructuring savings and revenue initiatives are beginning to contribute meaningfully in the second half of 2026 could improve investor sentiment.
What the Zacks Model Unveils for XRAYOur proven model does not conclusively predict an earnings beat for XRAY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
XRAY’s Earnings ESP:Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
XRAY’s Zacks Rank: DENTSPLY SIRONA currently carries a Zacks Rank #3.
Stocks to ConsiderHere are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rank stocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release third-quarter fiscal 2026 results on Aug. 5.
COR’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 1.59%. The Zacks Consensus Estimate for COR’s fiscal third-quarter EPS implies an improvement of 9.3% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank #2 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.
Dentsply Sirona rozšiřuje v Kanadě spolupráci s Medline Sinclair, která od 1. září začne nabízet její technologické portfolio po celé zemi. Cílem je zvýšit dostupnost řešení digitální stomatologie.
The expansion marks Dentsply Sirona's sixth dealer network enhancement announced in 2026, further advancing its strategy to broaden access to digital dentistry solutions through trusted distribution partners July 28, 2026 08:30 ET | Source: DENTSPLY SIRONA Inc.
CHARLOTTE, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- Dentsply Sirona, the world's largest diversified manufacturer of professional dental products and technologies, today announced an expansion of its long-standing relationship with Medline Sinclair, one of Canada's leading full-service dental distributors.
Effective September 1, 2026, Medline Sinclair will begin offering Dentsply Sirona's technology portfolio across Canada, building on a successful relationship that has historically focused on consumables. The expanded relationship increases access to Dentsply Sirona's digital dentistry solutions through Medline Sinclair's nationwide network of sales, service teams, and technical specialists.
Sinclair Dental was acquired by Medline Canada, Corporation in 2024 and as Medline Sinclair today, it is one of Canada’s largest manufacturers and distributors of healthcare and dental products and services from coast-to-coast. The company's strong reputation and broad geographic reach make it a valuable partner in delivering technology solutions to Canadian healthcare customers.
"Expanding access to our solutions through strong distribution partnerships is an important part of our North America strategy," said Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona. "The expansion of our relationship with Medline Sinclair represents the sixth dealer network enhancement we have announced in 2026 and reflects our continued commitment to strengthening our commercial reach across North America. Medline Sinclair's established presence and service capabilities make them an ideal partner to expand access to our technology portfolio across Canada and support practices as they modernize their workflows."
“Bringing innovative solutions that enable our customers to be as productive and profitable as possible is a key driver when making a decision to add a new brand. Dentsply Sirona’s technology portfolio fits this strategy and we look forward to a mutually beneficial relationship.” said Peter Jugoon, SVP, Dental for Medline Sinclair.
About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
Contact Information:
Dentsply Sirona Press Contact:
Marion Par-Weixlberger
Vice President, Corporate Communications, Public Relations & Brand [email protected]
